Login / Signup

Targeting host calcium channels and viroporins: a promising strategy for SARS-CoV-2 therapy.

Mona FaniMaryam MoossaviHasan BakhshiAbozar Nasiri JahrodiMohammad Reza KhazdairAmir Hossein ZardastShokouh Ghafari
Published in: Future virology (2023)
Despite passing the pandemic phase of the COVID-19, researchers are still investigating various drugs. Previous evidence suggests that blocking the calcium channels may be a suitable treatment option. Ca 2+ is required to enhance the fusion process of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Also, some important inflammatory factors during SARS-CoV-2 infection are dependent on Ca 2+ level. On the other hand, viroporins have emerged as attractive targets for antiviral therapy due to their essential role in viral replication and pathogenesis. By inhibiting the host calcium channels and viroporins, it is possible to limit the spread of infection. Therefore, calcium channel blockers (CCBs) and drugs targeting Viroporins can be considered an effective option in the fight against SARS-CoV-2.
Keyphrases
  • sars cov
  • respiratory syndrome coronavirus
  • coronavirus disease
  • cancer therapy
  • signaling pathway
  • oxidative stress
  • bone marrow
  • cell therapy
  • drug induced